Market Overview

Is Gilead Sciences About To Buy Vertex For $45 Billion?

Is Gilead Sciences About To Buy Vertex For $45 Billion?
Related GILD
Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
T Rowe Price Is Buying These 9 Stocks (GuruFocus)
Related VRTX
Goldman Says These 25 Healthcare Stocks Are Immune To The Election
7 Biggest Price Target Changes For Monday
Vertex Pharmaceuticals raises ORKAMBI guidance, shares +5.5% (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work.

In its Q4 earnings report, Gilead announced that its cash position had increased from $2.6 billion to $11.7 billion in one year. On top of quadrupling its bank account, Gilead repurchased $5.3 billion worth of stock throughout 2014. 

On April 21, Bernstein analyst Geoffrey Porges put out a note suggesting Gilead make a bid for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Vertex has a cystic fibrosis drug, which appears promising and could fetch huge returns. With Vertex's market cap at $30 billion, Porges' estimate of $45 billion seems reasonable. 

Gilead's biggest problem right now is a good one to have. The company is making so much money that it needs to find efficient ways to spend its cash. Thus far, management has been a steward of capital, avoiding high-risk maneuvers.

Gilead's largest expense in the past year was its share repurchase program. 

Aside from $5.3 billion in buybacks, Gilead's next largest expenditure was the acquisition of Phenex Pharmaceuticals reported back in January, which could cost up to $470 million.

With the acquisition of Phenex, Gilead wrapped its arms around several potential treatments for nonalcoholic steatohepatitis, a common liver disease.


Harvoni was FDA approved in October 2014 and drove a huge earnings beat for Gilead last quarter.

This quarter, Estimize contributors expect more of the same. The consensus estimate from 140 contributing analysts is that Gilead will report earnings of $2.48 per share on top of $7.04 billion in revenue. Compare that to the estimate from Wall Street: $2.16 in EPS and $6.76 billion in sales.

Since the release of Sovaldi in FQ1 2014, Gilead has trampled the Wall Street earnings consensus three times and reported in-line just once. When biotech companies release new drugs, the first two quarters after the release often show a great deal of uncertainty.

Here, the Estimize community is setting the bar high in a show of faith that Gilead will report a strong quarter.

The expectation from Estimize is that Harvoni will drive a 68 percent year over year increase to earnings and a 41 percent improvement in revenues. Apart from roaring financial results, investors will look to see if Gilead has figured out a way to spend its mountain of cash, potentially on a blockbuster acquisition.

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Bernstein Geoffrey PorgesBiotech News Rumors Previews Trading Ideas General Best of Benzinga


Related Articles (GILD + VRTX)

View Comments and Join the Discussion!